nodes	percent_of_prediction	percent_of_DWPC	metapath
Ketobemidone—CYP2B6—Efavirenz—acquired immunodeficiency syndrome	0.0495	0.0529	CbGbCtD
Ketobemidone—CYP2B6—Lopinavir—acquired immunodeficiency syndrome	0.0465	0.0498	CbGbCtD
Ketobemidone—CYP2B6—Nevirapine—acquired immunodeficiency syndrome	0.0465	0.0498	CbGbCtD
Ketobemidone—CYP2B6—Amprenavir—acquired immunodeficiency syndrome	0.0421	0.045	CbGbCtD
Ketobemidone—CYP2B6—Nelfinavir—acquired immunodeficiency syndrome	0.0352	0.0377	CbGbCtD
Ketobemidone—CYP2B6—Ritonavir—acquired immunodeficiency syndrome	0.0319	0.0341	CbGbCtD
Ketobemidone—CYP2C8—Delavirdine—acquired immunodeficiency syndrome	0.0319	0.0341	CbGbCtD
Ketobemidone—CYP2C8—Amprenavir—acquired immunodeficiency syndrome	0.0319	0.0341	CbGbCtD
Ketobemidone—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.0314	0.0336	CbGbCtD
Ketobemidone—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.0295	0.0316	CbGbCtD
Ketobemidone—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.0267	0.0286	CbGbCtD
Ketobemidone—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.0267	0.0286	CbGbCtD
Ketobemidone—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0261	0.028	CbGbCtD
Ketobemidone—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.0246	0.0263	CbGbCtD
Ketobemidone—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.0246	0.0263	CbGbCtD
Ketobemidone—CYP2C8—Saquinavir—acquired immunodeficiency syndrome	0.0241	0.0258	CbGbCtD
Ketobemidone—CYP2C8—Ritonavir—acquired immunodeficiency syndrome	0.0241	0.0258	CbGbCtD
Ketobemidone—CYP2C8—Zidovudine—acquired immunodeficiency syndrome	0.0231	0.0248	CbGbCtD
Ketobemidone—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.0231	0.0247	CbGbCtD
Ketobemidone—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.0224	0.024	CbGbCtD
Ketobemidone—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0222	0.0238	CbGbCtD
Ketobemidone—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0222	0.0238	CbGbCtD
Ketobemidone—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.0203	0.0217	CbGbCtD
Ketobemidone—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.0203	0.0217	CbGbCtD
Ketobemidone—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.0194	0.0208	CbGbCtD
Ketobemidone—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.0192	0.0205	CbGbCtD
Ketobemidone—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.0186	0.0199	CbGbCtD
Ketobemidone—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.0168	0.018	CbGbCtD
Ketobemidone—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.0168	0.018	CbGbCtD
Ketobemidone—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.0161	0.0173	CbGbCtD
Ketobemidone—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0152	0.0163	CbGbCtD
Ketobemidone—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0143	0.0153	CbGbCtD
Ketobemidone—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0143	0.0153	CbGbCtD
Ketobemidone—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0129	0.0138	CbGbCtD
Ketobemidone—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0129	0.0138	CbGbCtD
Ketobemidone—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0112	0.0119	CbGbCtD
Ketobemidone—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0108	0.0116	CbGbCtD
Ketobemidone—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00979	0.0105	CbGbCtD
Ketobemidone—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00979	0.0105	CbGbCtD
Ketobemidone—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00939	0.01	CbGbCtD
Ketobemidone—OPRM1—nerve—acquired immunodeficiency syndrome	0.0033	0.0868	CbGeAlD
Ketobemidone—UGT1A9—digestive system—acquired immunodeficiency syndrome	0.00178	0.0468	CbGeAlD
Ketobemidone—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.00172	0.0452	CbGeAlD
Ketobemidone—CYP2C8—blood plasma—acquired immunodeficiency syndrome	0.0015	0.0395	CbGeAlD
Ketobemidone—PTGS1—endothelium—acquired immunodeficiency syndrome	0.00137	0.0361	CbGeAlD
Ketobemidone—CYP2B6—blood plasma—acquired immunodeficiency syndrome	0.00135	0.0354	CbGeAlD
Ketobemidone—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.00133	0.0351	CbGeAlD
Ketobemidone—PTGS1—blood plasma—acquired immunodeficiency syndrome	0.00122	0.032	CbGeAlD
Ketobemidone—OPRD1—nervous system—acquired immunodeficiency syndrome	0.00109	0.0286	CbGeAlD
Ketobemidone—OPRD1—central nervous system—acquired immunodeficiency syndrome	0.00105	0.0276	CbGeAlD
Ketobemidone—OPRK1—nervous system—acquired immunodeficiency syndrome	0.00104	0.0274	CbGeAlD
Ketobemidone—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.00102	0.0268	CbGeAlD
Ketobemidone—OPRK1—central nervous system—acquired immunodeficiency syndrome	0.001	0.0264	CbGeAlD
Ketobemidone—OPRM1—blood—acquired immunodeficiency syndrome	0.000914	0.0241	CbGeAlD
Ketobemidone—OPRM1—spinal cord—acquired immunodeficiency syndrome	0.000881	0.0232	CbGeAlD
Ketobemidone—OPRD1—brain—acquired immunodeficiency syndrome	0.000832	0.0219	CbGeAlD
Ketobemidone—OPRK1—brain—acquired immunodeficiency syndrome	0.000798	0.021	CbGeAlD
Ketobemidone—OPRM1—nervous system—acquired immunodeficiency syndrome	0.000742	0.0195	CbGeAlD
Ketobemidone—OPRM1—central nervous system—acquired immunodeficiency syndrome	0.000715	0.0188	CbGeAlD
Ketobemidone—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000661	0.0174	CbGeAlD
Ketobemidone—CYP2B6—skin of body—acquired immunodeficiency syndrome	0.000647	0.017	CbGeAlD
Ketobemidone—CYP2C19—blood—acquired immunodeficiency syndrome	0.00063	0.0166	CbGeAlD
Ketobemidone—PTGS1—skin of body—acquired immunodeficiency syndrome	0.000585	0.0154	CbGeAlD
Ketobemidone—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000584	0.0154	CbGeAlD
Ketobemidone—OPRM1—brain—acquired immunodeficiency syndrome	0.000567	0.0149	CbGeAlD
Ketobemidone—CYP2C8—blood—acquired immunodeficiency syndrome	0.00055	0.0145	CbGeAlD
Ketobemidone—CYP2B6—lymphoid tissue—acquired immunodeficiency syndrome	0.000524	0.0138	CbGeAlD
Ketobemidone—CYP2B6—digestive system—acquired immunodeficiency syndrome	0.000518	0.0136	CbGeAlD
Ketobemidone—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000513	0.0135	CbGeAlD
Ketobemidone—CYP2C8—vagina—acquired immunodeficiency syndrome	0.00051	0.0134	CbGeAlD
Ketobemidone—CYP2B6—blood—acquired immunodeficiency syndrome	0.000493	0.013	CbGeAlD
Ketobemidone—CYP2C9—blood—acquired immunodeficiency syndrome	0.000489	0.0129	CbGeAlD
Ketobemidone—Pethidine—ALB—acquired immunodeficiency syndrome	0.000486	1	CrCbGaD
Ketobemidone—PTGS1—digestive system—acquired immunodeficiency syndrome	0.000468	0.0123	CbGeAlD
Ketobemidone—CYP2B6—vagina—acquired immunodeficiency syndrome	0.000457	0.012	CbGeAlD
Ketobemidone—PTGS1—blood—acquired immunodeficiency syndrome	0.000446	0.0117	CbGeAlD
Ketobemidone—CYP2B6—lung—acquired immunodeficiency syndrome	0.000432	0.0114	CbGeAlD
Ketobemidone—PTGS1—spinal cord—acquired immunodeficiency syndrome	0.00043	0.0113	CbGeAlD
Ketobemidone—PTGS1—vagina—acquired immunodeficiency syndrome	0.000413	0.0109	CbGeAlD
Ketobemidone—CYP2B6—nervous system—acquired immunodeficiency syndrome	0.000401	0.0105	CbGeAlD
Ketobemidone—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000391	0.0103	CbGeAlD
Ketobemidone—PTGS1—lung—acquired immunodeficiency syndrome	0.000391	0.0103	CbGeAlD
Ketobemidone—CYP2B6—central nervous system—acquired immunodeficiency syndrome	0.000386	0.0101	CbGeAlD
Ketobemidone—CYP3A4—blood—acquired immunodeficiency syndrome	0.000373	0.0098	CbGeAlD
Ketobemidone—PTGS1—nervous system—acquired immunodeficiency syndrome	0.000362	0.00952	CbGeAlD
Ketobemidone—PTGS1—central nervous system—acquired immunodeficiency syndrome	0.000349	0.00917	CbGeAlD
Ketobemidone—CYP2C8—brain—acquired immunodeficiency syndrome	0.000341	0.00898	CbGeAlD
Ketobemidone—OPRD1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.00034	0.0125	CbGpPWpGaD
Ketobemidone—OPRK1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.000333	0.0122	CbGpPWpGaD
Ketobemidone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000331	0.0121	CbGpPWpGaD
Ketobemidone—OPRD1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000308	0.0113	CbGpPWpGaD
Ketobemidone—CYP2B6—brain—acquired immunodeficiency syndrome	0.000306	0.00805	CbGeAlD
Ketobemidone—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000302	0.00796	CbGeAlD
Ketobemidone—OPRM1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.0003	0.011	CbGpPWpGaD
Ketobemidone—OPRK1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000299	0.011	CbGpPWpGaD
Ketobemidone—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000291	0.00766	CbGeAlD
Ketobemidone—OPRD1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000287	0.0105	CbGpPWpGaD
Ketobemidone—OPRM1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.000282	0.0103	CbGpPWpGaD
Ketobemidone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000279	0.0103	CbGpPWpGaD
Ketobemidone—PTGS1—brain—acquired immunodeficiency syndrome	0.000277	0.00728	CbGeAlD
Ketobemidone—OPRK1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00027	0.00991	CbGpPWpGaD
Ketobemidone—PTGS1—lymph node—acquired immunodeficiency syndrome	0.000267	0.00703	CbGeAlD
Ketobemidone—OPRD1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000261	0.00957	CbGpPWpGaD
Ketobemidone—OPRM1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000252	0.00927	CbGpPWpGaD
Ketobemidone—OPRK1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000252	0.00924	CbGpPWpGaD
Ketobemidone—OPRM1—IL4-mediated signaling events—IL10—acquired immunodeficiency syndrome	0.000246	0.00904	CbGpPWpGaD
Ketobemidone—OPRM1—IL4-mediated signaling events—CD40LG—acquired immunodeficiency syndrome	0.000246	0.00904	CbGpPWpGaD
Ketobemidone—OPRM1—IL4-mediated signaling events—IL4—acquired immunodeficiency syndrome	0.000239	0.00879	CbGpPWpGaD
Ketobemidone—OPRK1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000229	0.00839	CbGpPWpGaD
Ketobemidone—OPRD1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000228	0.00839	CbGpPWpGaD
Ketobemidone—OPRM1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000228	0.00838	CbGpPWpGaD
Ketobemidone—OPRM1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000213	0.00781	CbGpPWpGaD
Ketobemidone—OPRD1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.00021	0.00772	CbGpPWpGaD
Ketobemidone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000207	0.00758	CbGpPWpGaD
Ketobemidone—PTGS1—Overview of nanoparticle effects—TNF—acquired immunodeficiency syndrome	0.000201	0.00738	CbGpPWpGaD
Ketobemidone—OPRK1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.0002	0.00735	CbGpPWpGaD
Ketobemidone—OPRM1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000193	0.00709	CbGpPWpGaD
Ketobemidone—OPRD1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00019	0.00699	CbGpPWpGaD
Ketobemidone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	0.000188	0.0069	CbGpPWpGaD
Ketobemidone—OPRK1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000184	0.00677	CbGpPWpGaD
Ketobemidone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000181	0.00665	CbGpPWpGaD
Ketobemidone—OPRM1—TCR Signaling Pathway—CD8A—acquired immunodeficiency syndrome	0.000181	0.00663	CbGpPWpGaD
Ketobemidone—OPRD1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000179	0.00657	CbGpPWpGaD
Ketobemidone—OPRD1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000179	0.00657	CbGpPWpGaD
Ketobemidone—OPRD1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000174	0.00639	CbGpPWpGaD
Ketobemidone—OPRM1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000169	0.00621	CbGpPWpGaD
Ketobemidone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	0.000167	0.00613	CbGpPWpGaD
Ketobemidone—OPRK1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000167	0.00613	CbGpPWpGaD
Ketobemidone—OPRM1—TCR Signaling Pathway—CCR5—acquired immunodeficiency syndrome	0.000165	0.00606	CbGpPWpGaD
Ketobemidone—PTGS1—Overview of nanoparticle effects—IL6—acquired immunodeficiency syndrome	0.000162	0.00596	CbGpPWpGaD
Ketobemidone—OPRD1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.00016	0.00589	CbGpPWpGaD
Ketobemidone—OPRD1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000157	0.00578	CbGpPWpGaD
Ketobemidone—OPRK1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000157	0.00576	CbGpPWpGaD
Ketobemidone—OPRK1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000157	0.00576	CbGpPWpGaD
Ketobemidone—OPRM1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000156	0.00572	CbGpPWpGaD
Ketobemidone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000153	0.00562	CbGpPWpGaD
Ketobemidone—OPRK1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000152	0.0056	CbGpPWpGaD
Ketobemidone—OPRD1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000151	0.00554	CbGpPWpGaD
Ketobemidone—OPRD1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000151	0.00554	CbGpPWpGaD
Ketobemidone—OPRD1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000149	0.00547	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000147	0.00541	CbGpPWpGaD
Ketobemidone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000141	0.00518	CbGpPWpGaD
Ketobemidone—OPRM1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000141	0.00518	CbGpPWpGaD
Ketobemidone—OPRK1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000141	0.00517	CbGpPWpGaD
Ketobemidone—OPRD1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00014	0.00514	CbGpPWpGaD
Ketobemidone—OPRK1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000138	0.00506	CbGpPWpGaD
Ketobemidone—OPRD1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000136	0.005	CbGpPWpGaD
Ketobemidone—UGT1A9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	0.000134	0.00493	CbGpPWpGaD
Ketobemidone—OPRM1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000133	0.00487	CbGpPWpGaD
Ketobemidone—OPRM1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000133	0.00487	CbGpPWpGaD
Ketobemidone—OPRK1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000132	0.00486	CbGpPWpGaD
Ketobemidone—OPRK1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000132	0.00486	CbGpPWpGaD
Ketobemidone—OPRK1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000131	0.0048	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000129	0.00474	CbGpPWpGaD
Ketobemidone—OPRM1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000129	0.00473	CbGpPWpGaD
Ketobemidone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000128	0.00469	CbGpPWpGaD
Ketobemidone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000124	0.00454	CbGpPWpGaD
Ketobemidone—OPRK1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000123	0.00451	CbGpPWpGaD
Ketobemidone—OPRD1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000123	0.0045	CbGpPWpGaD
Ketobemidone—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	0.000122	0.00447	CbGpPWpGaD
Ketobemidone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.00012	0.00441	CbGpPWpGaD
Ketobemidone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.00012	0.00441	CbGpPWpGaD
Ketobemidone—OPRK1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000119	0.00438	CbGpPWpGaD
Ketobemidone—OPRM1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000119	0.00437	CbGpPWpGaD
Ketobemidone—OPRM1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000117	0.00428	CbGpPWpGaD
Ketobemidone—OPRD1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000115	0.00421	CbGpPWpGaD
Ketobemidone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000112	0.00411	CbGpPWpGaD
Ketobemidone—OPRM1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000112	0.00411	CbGpPWpGaD
Ketobemidone—OPRM1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000112	0.00411	CbGpPWpGaD
Ketobemidone—OPRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00011	0.00405	CbGpPWpGaD
Ketobemidone—PTGS1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	0.000109	0.00402	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000109	0.00401	CbGpPWpGaD
Ketobemidone—OPRK1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000107	0.00395	CbGpPWpGaD
Ketobemidone—OPRD1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000107	0.00395	CbGpPWpGaD
Ketobemidone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000105	0.00386	CbGpPWpGaD
Ketobemidone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000105	0.00386	CbGpPWpGaD
Ketobemidone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000105	0.00384	CbGpPWpGaD
Ketobemidone—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000104	0.00381	CbGpPWpGaD
Ketobemidone—OPRM1—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	0.000104	0.00381	CbGpPWpGaD
Ketobemidone—OPRD1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000103	0.0038	CbGpPWpGaD
Ketobemidone—OPRM1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000101	0.0037	CbGpPWpGaD
Ketobemidone—OPRK1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000101	0.0037	CbGpPWpGaD
Ketobemidone—PTGS1—Selenium Micronutrient Network—ALB—acquired immunodeficiency syndrome	9.99e-05	0.00367	CbGpPWpGaD
Ketobemidone—OPRD1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	9.72e-05	0.00357	CbGpPWpGaD
Ketobemidone—OPRD1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	9.6e-05	0.00352	CbGpPWpGaD
Ketobemidone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	9.46e-05	0.00347	CbGpPWpGaD
Ketobemidone—OPRK1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	9.42e-05	0.00346	CbGpPWpGaD
Ketobemidone—OPRD1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	9.14e-05	0.00335	CbGpPWpGaD
Ketobemidone—OPRD1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	9.14e-05	0.00335	CbGpPWpGaD
Ketobemidone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	9.13e-05	0.00335	CbGpPWpGaD
Ketobemidone—PTGS1—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	9.11e-05	0.00335	CbGpPWpGaD
Ketobemidone—OPRM1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	9.08e-05	0.00334	CbGpPWpGaD
Ketobemidone—OPRK1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	9.07e-05	0.00333	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	8.92e-05	0.00328	CbGpPWpGaD
Ketobemidone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	8.89e-05	0.00326	CbGpPWpGaD
Ketobemidone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	8.89e-05	0.00326	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	8.7e-05	0.0032	CbGpPWpGaD
Ketobemidone—OPRK1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	8.52e-05	0.00313	CbGpPWpGaD
Ketobemidone—OPRM1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	8.51e-05	0.00312	CbGpPWpGaD
Ketobemidone—OPRK1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	8.41e-05	0.00309	CbGpPWpGaD
Ketobemidone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	8.22e-05	0.00302	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	8.07e-05	0.00296	CbGpPWpGaD
Ketobemidone—OPRK1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	8.01e-05	0.00294	CbGpPWpGaD
Ketobemidone—OPRK1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	8.01e-05	0.00294	CbGpPWpGaD
Ketobemidone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	8e-05	0.00294	CbGpPWpGaD
Ketobemidone—OPRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	7.96e-05	0.00292	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	7.83e-05	0.00287	CbGpPWpGaD
Ketobemidone—OPRM1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	7.66e-05	0.00281	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	7.63e-05	0.0028	CbGpPWpGaD
Ketobemidone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	7.21e-05	0.00265	CbGpPWpGaD
Ketobemidone—OPRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	7.2e-05	0.00264	CbGpPWpGaD
Ketobemidone—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	7.11e-05	0.00261	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	7.08e-05	0.0026	CbGpPWpGaD
Ketobemidone—CYP2C8—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	7.07e-05	0.0026	CbGpPWpGaD
Ketobemidone—UGT1A9—Metabolism—TAT—acquired immunodeficiency syndrome	7.03e-05	0.00258	CbGpPWpGaD
Ketobemidone—OPRD1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	6.95e-05	0.00255	CbGpPWpGaD
Ketobemidone—OPRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	6.77e-05	0.00249	CbGpPWpGaD
Ketobemidone—OPRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	6.77e-05	0.00249	CbGpPWpGaD
Ketobemidone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	6.76e-05	0.00248	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	6.61e-05	0.00243	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	6.45e-05	0.00237	CbGpPWpGaD
Ketobemidone—CYP2C19—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	6.31e-05	0.00232	CbGpPWpGaD
Ketobemidone—OPRD1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	6.26e-05	0.0023	CbGpPWpGaD
Ketobemidone—OPRK1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	6.09e-05	0.00224	CbGpPWpGaD
Ketobemidone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	6.09e-05	0.00224	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.98e-05	0.0022	CbGpPWpGaD
Ketobemidone—UGT1A9—Metabolism—AGPS—acquired immunodeficiency syndrome	5.98e-05	0.00219	CbGpPWpGaD
Ketobemidone—PTGS1—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	5.9e-05	0.00217	CbGpPWpGaD
Ketobemidone—CYP2C9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	5.75e-05	0.00211	CbGpPWpGaD
Ketobemidone—PTGS1—Metabolism—TAT—acquired immunodeficiency syndrome	5.73e-05	0.0021	CbGpPWpGaD
Ketobemidone—OPRM1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	5.61e-05	0.00206	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.51e-05	0.00202	CbGpPWpGaD
Ketobemidone—OPRD1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.49e-05	0.00202	CbGpPWpGaD
Ketobemidone—OPRK1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.49e-05	0.00202	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.27e-05	0.00194	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.27e-05	0.00194	CbGpPWpGaD
Ketobemidone—OPRD1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.16e-05	0.0019	CbGpPWpGaD
Ketobemidone—OPRD1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.16e-05	0.0019	CbGpPWpGaD
Ketobemidone—OPRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.15e-05	0.00189	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.99e-05	0.00183	CbGpPWpGaD
Ketobemidone—PTGS1—Metabolism—AGPS—acquired immunodeficiency syndrome	4.87e-05	0.00179	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.83e-05	0.00178	CbGpPWpGaD
Ketobemidone—OPRK1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.81e-05	0.00177	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.77e-05	0.00175	CbGpPWpGaD
Ketobemidone—PTGS1—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	4.76e-05	0.00175	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.69e-05	0.00172	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.69e-05	0.00172	CbGpPWpGaD
Ketobemidone—OPRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.64e-05	0.0017	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.62e-05	0.0017	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.62e-05	0.0017	CbGpPWpGaD
Ketobemidone—OPRK1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.53e-05	0.00166	CbGpPWpGaD
Ketobemidone—OPRK1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.53e-05	0.00166	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.37e-05	0.00161	CbGpPWpGaD
Ketobemidone—CYP2B6—Metabolism—TAT—acquired immunodeficiency syndrome	4.37e-05	0.00161	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.18e-05	0.00154	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.11e-05	0.00151	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.11e-05	0.00151	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.09e-05	0.0015	CbGpPWpGaD
Ketobemidone—OPRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.07e-05	0.00149	CbGpPWpGaD
Ketobemidone—OPRD1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.93e-05	0.00144	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.91e-05	0.00143	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.91e-05	0.00143	CbGpPWpGaD
Ketobemidone—OPRD1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.87e-05	0.00142	CbGpPWpGaD
Ketobemidone—OPRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.83e-05	0.0014	CbGpPWpGaD
Ketobemidone—OPRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.83e-05	0.0014	CbGpPWpGaD
Ketobemidone—CYP2B6—Metabolism—AGPS—acquired immunodeficiency syndrome	3.72e-05	0.00137	CbGpPWpGaD
Ketobemidone—CYP2C8—Metabolism—TAT—acquired immunodeficiency syndrome	3.7e-05	0.00136	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.7e-05	0.00136	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.57e-05	0.00131	CbGpPWpGaD
Ketobemidone—OPRD1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.54e-05	0.0013	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.53e-05	0.0013	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.51e-05	0.00129	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.47e-05	0.00128	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.47e-05	0.00128	CbGpPWpGaD
Ketobemidone—OPRK1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.44e-05	0.00126	CbGpPWpGaD
Ketobemidone—OPRK1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.39e-05	0.00125	CbGpPWpGaD
Ketobemidone—CYP2C19—Metabolism—TAT—acquired immunodeficiency syndrome	3.3e-05	0.00121	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.26e-05	0.0012	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.21e-05	0.00118	CbGpPWpGaD
Ketobemidone—CYP2C8—Metabolism—AGPS—acquired immunodeficiency syndrome	3.15e-05	0.00116	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.13e-05	0.00115	CbGpPWpGaD
Ketobemidone—OPRK1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.1e-05	0.00114	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.08e-05	0.00113	CbGpPWpGaD
Ketobemidone—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	3.01e-05	0.00111	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.95e-05	0.00108	CbGpPWpGaD
Ketobemidone—OPRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.91e-05	0.00107	CbGpPWpGaD
Ketobemidone—OPRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.87e-05	0.00105	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.86e-05	0.00105	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.82e-05	0.00103	CbGpPWpGaD
Ketobemidone—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	2.81e-05	0.00103	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.77e-05	0.00102	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.77e-05	0.00102	CbGpPWpGaD
Ketobemidone—UGT1A9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.75e-05	0.00101	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.64e-05	0.000971	CbGpPWpGaD
Ketobemidone—OPRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.62e-05	0.000963	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.6e-05	0.000956	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.58e-05	0.000948	CbGpPWpGaD
Ketobemidone—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	2.56e-05	0.000941	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.43e-05	0.000892	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.43e-05	0.000892	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.41e-05	0.000886	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.38e-05	0.000874	CbGpPWpGaD
Ketobemidone—PTGS1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.24e-05	0.000824	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.18e-05	0.000802	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.11e-05	0.000774	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.08e-05	0.000762	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.05e-05	0.000754	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.05e-05	0.000754	CbGpPWpGaD
Ketobemidone—OPRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.04e-05	0.000751	CbGpPWpGaD
Ketobemidone—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	1.99e-05	0.00073	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.9e-05	0.000697	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.86e-05	0.000682	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.85e-05	0.000678	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.82e-05	0.000668	CbGpPWpGaD
Ketobemidone—OPRK1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.79e-05	0.000658	CbGpPWpGaD
Ketobemidone—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	1.69e-05	0.00062	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.66e-05	0.000611	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.63e-05	0.000598	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.56e-05	0.000573	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.54e-05	0.000565	CbGpPWpGaD
Ketobemidone—OPRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.52e-05	0.000556	CbGpPWpGaD
Ketobemidone—CYP2C8—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.45e-05	0.000532	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.41e-05	0.000517	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.38e-05	0.000505	CbGpPWpGaD
Ketobemidone—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.29e-05	0.000475	CbGpPWpGaD
Ketobemidone—UGT1A9—Metabolism—ALB—acquired immunodeficiency syndrome	1.23e-05	0.00045	CbGpPWpGaD
Ketobemidone—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.18e-05	0.000433	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.1e-05	0.000403	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.09e-05	0.000401	CbGpPWpGaD
Ketobemidone—PTGS1—Metabolism—ALB—acquired immunodeficiency syndrome	9.99e-06	0.000367	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.62e-06	0.000353	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.57e-06	0.000351	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.13e-06	0.000298	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.09e-06	0.000297	CbGpPWpGaD
Ketobemidone—CYP2B6—Metabolism—ALB—acquired immunodeficiency syndrome	7.62e-06	0.00028	CbGpPWpGaD
Ketobemidone—CYP2C8—Metabolism—ALB—acquired immunodeficiency syndrome	6.45e-06	0.000237	CbGpPWpGaD
Ketobemidone—OPRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.45e-06	0.000237	CbGpPWpGaD
Ketobemidone—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	5.76e-06	0.000212	CbGpPWpGaD
Ketobemidone—OPRK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.65e-06	0.000208	CbGpPWpGaD
Ketobemidone—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	5.25e-06	0.000193	CbGpPWpGaD
Ketobemidone—OPRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.78e-06	0.000175	CbGpPWpGaD
Ketobemidone—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	3.46e-06	0.000127	CbGpPWpGaD
